Home | EndoTODAY | EndoATLAS


[¼ÒÈ­±â³»°ú ºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À°]


¿ÀÀü ÇÁ·Î±×·¥. ¿ÀÈÄ¿¡´Â °£°ú Ãé´ãµµ °­ÀÇ°¡ ÀÖ¾ú½À´Ï´Ù.


1. ½Äµµ¾Ï. ¼º±Õ°üÀÇ´ë ÀÌÁØÇà

Àú´Â ½Äµµ¾Ï¿¡ ´ëÇÑ °­ÀǸ¦ ÇÏ¿´½À´Ï´Ù. ½Ã°£ÀÌ Âª¾Ò±â ¶§¹®¿¡ Áß¿äÇÑ °ÍÀ» Áß½ÉÀ¸·Î ¸»¾¸µå·È½À´Ï´Ù. ½Äµµ¾Ï¿¡ ´ëÇؼ­´Â 2013³â 1¿ù 12ÀÏ EndoTODAYºÎÅÍ ¸î ÁÖÀÏ µ¿¾È ÀÚ¼¼È÷ ³íÇÏ¿´½À´Ï´Ù. Âü°íÇϽñ⠹ٶø´Ï´Ù.

½Äµµ¾ÏÀº superficial spreadingÀ» ÇÒ ¼ö ÀÖÀ¸¹Ç·Î º´¼ÒÀÇ proximal marginÀ» Á¤È®È÷ Æò°¡ÇØ¾ß ÇÕ´Ï´Ù. ¼ö¼ú ÈÄ resection marginÀÌ ¾ç¼ºÀ¸·Î ³ª¿À¸é ¹«Ã´ °ï¶õÇϱ⠶§¹®ÀÔ´Ï´Ù.

°£È¤ ½Äµµ »óÇǾÏÀÌ gland¸¦ µû¶ó¼­ Á¡¸·ÇÏÃþ±îÁö spread µÇ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. ¾Æ·¡ Áõ·ÊÀÇ º´¸®°á°ú¸¦ Âü°íÇϽñ⠹ٶø´Ï´Ù.

Squamous cell carcinoma, in-situ :
1) size: up to 12 mm
2) marked glandular extension
3) no involvement of margin (see note)
Note: In some section, tumor cell nest of glandular extension (not true invasion) is very close to deep margins.


»ï¼º¼­¿ïº´¿øÀÇ T1 ½Äµµ¾Ï ¸²ÇÁÀý ÀüÀÌ À§Ç輺À» ºÐ¼®ÇÑ ¹Ù ÀÖ½À´Ï´Ù (J Gastroenterol Hepatol 2008). M3 ½Äµµ¾Ï¿¡¼­ ¸²ÇÁÀý ÀüÀÌ°¡ ÀûÁö ¾Ê°í, SM ¾Ï¿¡¼­´Â ´õ¿í ¸¹´Ù´Â Á¡ÀÌ Áß¿äÇÒ °Í °°½À´Ï´Ù. À§¾Ï¿¡¼­µµ depth of invasion¿¡ µû¶ó ¸²ÇÁÀý ÀüÀÌ°¡ ¸¹¾ÆÁöÁö¸¸ ½Äµµ¾Ï¿¡¼­´Â ±× Â÷ÀÌ°¡ ´õ¿í ÇöÀúÇÕ´Ï´Ù.

Larger

¸²ÇÁÀý ÀüÀ̸¦ °¡Áø M3 ½Äµµ¾ÏÀº ´ëºÎºÐ Àå°æ 20mm ÀÌ»óÀ̾ú½À´Ï´Ù. Àå°æ 10 mm ºÐÈ­Çü M3 ½Äµµ¾Ï¿¡¼­ ¸²ÇÁÀý ÀüÀ̵µ ÀÖ¾ú½À´Ï´Ù.

Larger


Submucosal invasionÀ» º¸ÀÎ ½Äµµ¾Ï (SM) Áß lymph node metastasis°¡ ¾ø¾ú´ø Áõ·Ê »çÁøÀ» ¸î Àå ¸ð¾Ò½À´Ï´Ù.


Submucosal invasionÀ» º¸ÀÎ ½Äµµ¾Ï (SM) Áß lymph node metastasis°¡ ÀÖ¾ú´ø Áõ·Ê »çÁøÀ» ¸î Àå ¸ð¾Ò½À´Ï´Ù.


LN 1/53


LN 1/10


LN 1/22


LN 1/33


LN 2/46


LN 2/16


LN 2/43


LN 2/49


LN 2/40


LN 10/29



2. ´ëÀå³»½Ã°æ °Ë»ç¸¦ ´õ ÀßÇϱâ À§ÇÑ ³ëÇÏ¿ì. °¡Å縯´ëÇб³ À̺¸ÀÎ

1. ÀßÇÏ´Â ³»½Ã°æÀº »¡¸® µé¾î°¡´Â ³»½Ã°æÀ» ¸»ÇÏ´Â °ÍÀÌ ¾Æ´Õ´Ï´Ù. ÁúÁöÇ¥°¡ ÁÁÀº ³»½Ã°æÀÌ ÀßÇÏ´Â ³»½Ã°æÀÔ´Ï´Ù.

2. ´ëÀå³»½Ã°æ °Ë»ç¸¦ ÀÚÁÖÇϸé interval cancer¸¦ ÁÙÀÏ ¼ö ÀÖÀ»±î¿ä? ¿¬±¸ °á°ú´Â ±×·¸Áö ¾Ê´Ù´Â °ÍÀÔ´Ï´Ù. °Ë»ç¸¦ ÀÚÁÖ Çؼ­ interval cancer¸¦ ÁÙÀÏ ¼ö ¾ø°í, Çѹø ÇÏ´Â °Ë»ç¸¦ Àß ÇØ¾ß interval cancer¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. Quality colonoscopy!!!

3. Quality metrics

1) screening/surveillance interval
2) bowel preparation quality
3) cecal intubation rate
4) adenoma detection rate - Kaminski. NEJM 2010;362:1795-1803 ADR°¡ ³ôÀº Àǻ翡°Ô ´ëÀå³»½Ã°æÀ» ¹ÞÀº °æ¿ì interval cancer°¡ Àû´Ù´Â ¿¬±¸ÀÔ´Ï´Ù. (¾Æ·¡ ±×¸² ÂüÁ¶)
5) withdrawal time - Æò±Õ 6ºÐ ÀÌ»óÀ» ÁöÅ°´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. Individual patient¿¡¼­ ¸ðµÎ 6ºÐÀ» ³Ñ¾î¾ß ÇÑ´Ù´Â °ÍÀ» ¸»ÇÏ´Â °ÍÀº ¾Æ´Õ´Ï´Ù.
6) complications
7) documentation


The graph shows cumulative hazard rates for interval colorectal cancer among subjects who underwent screening colonoscopy that was performed by an endoscopist with an ADR in one of the following categories: less than 11.0%, 11.0 to 14.9%, 15.0 to 19.9%, and 20.0% or more.

4. Bowel preparation Á¤µµ¸¦ ±â¼úÇÏ´Â ½À°üÀ» °®´Â °ÍÀÌ ÁÁ½À´Ï´Ù. ¼¼ °¡Áö ¹æ¹ýÀÌ Àִµ¥ º¸½ºÅæ¹ýÀÌ ¸¹ÀÌ ¾²ÀÔ´Ï´Ù.

1) Aronchick bowel preparation scale - excellent, good, fair, poor, inadequate
2) Ottawa bowel preparation scale - excellent, good, fair, poor, inadequate
3) Boston bowel preparation scale - excellent, good, poor, inadequate


3. ´ëÀå ¿ëÁ¾. ¼º±Õ°üÀÇ´ë ¹Úµ¿ÀÏ

1. ÇöÀç ¿ì¸®´Ï¶ó¿¡¼­ ´ëÀå¾ÏÀº ¸Å³â 6.2%¾¿ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù (2011³â º¸°Çº¹ÁöºÎ). ¸Å³â 25.3%¿¡¼­ Áõ°¡ÇÏ°í ÀÖ´Ù´Â °©»ó¼±¾ÏÀ» Á¦¿ÜÇÏ°í ´ëºÎºÐÀÇ ¾ÏÀº ´õ ÀÌ»ó Áõ°¡ÇÏÁö ¾Ê°í Àְųª °¨¼ÒÇϱ⠽ÃÀÛÇÑ °Í°ú´Â ´ëÁ¶ÀûÀÔ´Ï´Ù.

2. ÃÖ±Ù adenoma detection rate´Â ²ÙÁØÈ÷ »ó½ÂµÇ°í ÀÖ½À´Ï´Ù. 50´ë ÀÌ»ó ³²¼ºÀÇ °æ¿ì 55% ÀÌ»óÀÔ´Ï´Ù.

3. Serrated adenoma¿¡¼­ ¹ß»ýÇÏ´Â ¾ÏÀÇ °æ¿ì À۾Ƶµ verticalÇÏ°Ô ÀÚ¶ó´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ¹ß°ßµµ ¾î·Á¿ì¹Ç·Î ÁÖÀÇÇØ¾ß ÇÕ´Ï´Ù.

4. 5¹Ð¸® ÀÌÇÏÀÇ ¼±Á¾À» cold biopsy·Î Á¦°ÅÇÒ ¶§ 39%(21/54)¿¡¼­¸¸ Á¦°ÅµÈ´Ù´Â º¸°í°¡ ÀÖ¾ú½À´Ï´Ù (Ethymiou. Endoscopy 2011;43:312). ±×·¯³ª °­ºÏ»ï¼ºº´¿ø¿¡¼­ µ¿ÀÏÇÑ ÇÁ·ÎÅäÄÝ·Î ½ÃÇàÇÑ ¿¬±¸¿¡ µû¸£¸é 90.7%(78/86)ÀÇ 5¹Ð¸® ÀÌÇÏ ¼±Á¾ÀÌ cold biopsy·Î ¿ÏÀüÈ÷ Á¦°ÅµÇ¾ú½À´Ï´Ù (Jung. Endoscopy 2013:45:1024). ¾ó¸¶³ª ½Å°æ½á¼­ Ä¡·áÇϴ°¡¿¡ µû¶ó¼­ °á°ú°¡ »ó´çÈ÷ ´Þ¶óÁüÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù. ¹Úµ¿ÀÏ ±³¼ö´ÔÀº º´¼Ò¿¡ Á÷°¢À¸·Î Á¢±ÙÇϸé ÁÁ´Ù´Â tipÀ» ¾Ë·ÁÁּ̽À´Ï´Ù.

5. Defiant polyp = lesion that defies resection by the standard snare polypectomy

1) > 2 cm, flat, sessile
2) Àå°ü µÑ·¹ÀÇ 1/3ÀÌ»ó, haustral fold µÎ °³ ÀÌ»óÀ» ħÀ±
3) location - IC valve, appendiceal orfice°¡ º´º¯ÀÇ Áß¾Ó¿¡ À§Ä¡
4) ³»½Ã°æÀ» 5-6½Ã ¹æÇâÀ¸·Î °íÁ¤½ÃÅ°±â ¾î·Á¿î °æ¿ì
5) °Ô½Ç¿¡ ÀÎÁ¢Çϰųª °Ô½ÇÀÇ ³»ºÎ¿¡ ÀÖ´Â Æú¸³

6. Korean guideline for postpolypectomy surveillance (Yang DH. Clin Endosc 2012;45:44-61)

1) High risk group - surveillance after 3 years
- >= 3 adenomas
- any adenoma larger than 10 mm
- VTA or VA
- HGD
- SSP >= 10 mm
2) Without any high-risk findings; surveillance after 5 years


[±³À°À§¿øÀå´Ô²² µå¸®´Â Á¦¾È]

±³¼ö´Ô²².

³»³âµµ Çà»ç¸¦ À§ÇÏ¿© ÇÑ °¡Áö ÀÇ°ßÀ» ¿Ã¸³´Ï´Ù. ¸¹Àº ±³¼ö´ÔµéÀÌ Á¤¸» ¿­½ÉÈ÷ ÁغñÇϽŠ°Í °°½À´Ï´Ù. ÇϳªÇϳª ÁÖ¿Á°°Àº °­ÀÇ¿´½À´Ï´Ù. ±³‚æÀ§¿øȸ ¿©·¯ºÐµéÀÌ Á¤¸» °í»ýÀ» ¸¹ÀÌ ÇϽŠ°Í °°½À´Ï´Ù.

ÇÑ °¡Áö ¸»¾¸µå¸± ³»¿ëÀº ÀϺΠ¼±»ý´ÔµéÀÇ °æ¿ì °­ÀÇ ½½¶óÀ̵å¿Í ÇÚµå¾Æ¿ôÀÇ ³»¿ëÀÌ ´Þ¶ú½À´Ï´Ù. ¿ÁÀÇ Æ¼°¡ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù. ÄÁÅÄÃ÷º¸´Ù´Â story, story º¸´Ù´Â storytellingÀÌ Áß¿äÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù. °­ÀÇ Á÷Àü¿¡ ÄÁÅÄÃ÷¸¦ ¹Ù²Ù´Â °ÍÀÌ ¾ó¸¶³ª È¿°úÀûÀÏÁö Àǹ®ÀÔ´Ï´Ù.

½½¶óÀ̵å·Î ÇÚµå¾Æ¿ôÀ» ¸¸µé¾î ¹èÆ÷ÇÑ »óȲ¿¡¼­ ¸¶Áö¸·¿¡ ½½¶óÀ̵带 °íÃÄ °­ÀÇÇÏ´Â °ÍÀº ûÁßÀÇ ÁýÁßµµ¸¦ ³·Ã߱⠽±½À´Ï´Ù. °­»çÀÇ ¸»°ú È­¸éÀ» ¸ø º¸°í ÇÚµå¾Æ¿ôÀ» µÚÀû°Å¸®´Â ûÁßÀÌ ÀûÁö ¾Ê¾Ò½À´Ï´Ù.

°¨È÷ Á¦¾ÈÀ» ¿Ã¸³´Ï´Ù. ´ÙÀ½ Çà»ç¸¦ ÁغñÇÏ´Â °úÁ¤¿¡¼­´Â ¿¬Àڵ鿡°Ô ÀÌ Á¡À» ÁÖÁö½ÃÄÑÁÖ¸é ÁÁ°Ú½À´Ï´Ù. ÇÚµå¾Æ¿ô°ú °­Àǽ½¶óÀ̵å ÀÏÄ¡¸¦ ÁÖ¹®ÇØ Áֽñ⠹ٶø´Ï´Ù.

±ä ±Û ÀоîÁּż­ °¨»çÇÕ´Ï´Ù.

2014. 6. 15. ÀÌÁØÇà ¿Ã¸²